Menu ×

HEALTHCARE & PHARMACEUTICAL

Hematology Diagnostics Market Segmentation By Product (Reagents, Instruments & Analyzers and Software & Services); By Portability (Point-Of-Care [POC] Devices and Standalone Devices); By Application (Oncology, Malaria, Anemia [Sickle Cell Anemia, Thalassemia and Others], Blood Count, Platelet Function and Others); By End User (Hospitals, Diagnostic Labs, Ambulatory Surgical Centers, Clinics and Others) – Global Industry Demand Analysis and Opportunity Assessment 2018-2027

  • Text Size:

Extensive insights into the Growth of Hematology Diagnostics Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More
IN THE NEWS
  • On October 21, 2019, Beckman Coulter commercially launched its new DxH 690T hematology analyzer which is designed to maximize the uptime in laboratories while streamlining the workflow.
  • On January 2, 2018, Abbott announced the CE mark for its hematology testing Alinity h-series integrated system. The new Alinity h-series solution is 20% faster than other systems and provides a higher throughput of 133 complete blood counts per m2.

Market Overview

Hematology diagnostics includes various tests that are performed on blood samples in order to measure the number of red blood cells, white blood cells, platelets and other components of blood. It is a much faster and easier method for the detection of any disorder in the patients. The market for hematology diagnostics is projected to grow with a CAGR of 6.06% during the forecast period, i.e., 2020-2027. This can be attributed to the rising demand for advanced diagnostic technologies across the world. The requirement for diagnostic techniques that provide accurate test results and are capable of handling large sample processing volumes is another factor estimated to result in the market growth.

Growth Highlights based on Region during 2018-2027

The global hematology diagnostics market is segmented by regions into North America, Latin America, Europe, Asia-Pacific and Middle East and Africa. The hematology diagnostics market in North America held the largest market share of 37.94% in 2018 and is anticipated to continue to lead the market. The increasing investments in healthcare by the government and private organizations in order to maintain a high quality of healthcare at facilities is the major factor contributing towards the growth of market in this region. The market in the United States reached a value of USD 1,567.36 Million in 2018 and is predicted to observe a CAGR of 6.23% over the forecast period, which makes it the major country driving the market growth in North America. The growth can be attributed to the increasing adoption of innovative diagnostic methods that are focused on minimal in-vitro diagnostics. The market in Asia Pacific is estimated to witness the highest growth in the upcoming years on account of growing demand as well as availability of advanced healthcare technologies and services in the region. Additionally, the growing demand is met by a rising number of manufacturers in the industry investing in countries such as China, India and Japan. Hematology diagnostics market in Europe is anticipated to be driven by countries including Germany, UK, France and Italy as a result of a high demand for effective diagnostic products. CLICK TO DOWNLOAD SAMPLE REPORT

The study further incorporates Y-O-Y Growth, demand & supply and forecast future opportunity in North America (United States, Canada), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

Market Segmentation Synopsis

By Product

The market for hematology devices is segmented on the basis of product into reagents, instruments & analyzers and software & services. Reagents are used in hematology analyzers for lysing the red blood cells from the blood sample before leukocyte analysis. The segment for reagents is estimated to hold the largest market size and grow at the highest rate during the forecast period as a result of low cost of production, growing availability of reagents for specific analyzer tests and increasing number of tests being demanded by people. The instruments and analyzers segment is estimated to grow since hematology analyzers are the most commonly used instruments in clinical laboratories. The software and services segment is anticipated to observe noteworthy growth on account of growing compatibility of software with medical devices. The use of software improves the workflow by authorizing the results automatically and by supporting multi-instrument connectivity.

Hematology-Diagnostics-Market

By Portability

On the basis of portability, the market is bifurcated into point of care devices and standalone devices. The segment for point of care devices is anticipated to grow at the highest rate as a result of growing developments in these devices to improve the accuracy of patient diagnosis. These analyzers possess the ability to identify abnormal red blood cell count which might indicate anemia, leukemia, tumors and others. The standalone devices segment presently holds the largest market share as a result of its capability of producing high throughput results, mainly in larger healthcare facilities.

By Application

Hematology diagnostics market is segmented on the basis of application into oncology, malaria, anemia (sickle cell anemia, thalassemia and others), blood count, platelet function and others. The market segment estimated to witness the highest growth is the oncology segment. This can be attributed to the huge applications of hematology diagnosis in cases of cancer. Both point of care and standalone devices are used for hematology analysis of patients undergoing chemotherapy.

Hematology-Diagnostics-Market-Size

By End User

Based on end user, the market is segmented into hospitals, diagnostic labs, ambulatory surgical centers (ASCs), clinics and others, out of which, the hospitals segment is predicted to grow at a significantly high rate. This can be attributed to the high patient influx in hospitals as compared to other healthcare facilities and a growing number of registered hospitals across the globe.

Market Drivers and Challenges

Growth Indicators

The major growth driving factor for the hematology diagnostics market is the rising prevalence of blood disorders. Advanced hematology diagnostic products help in the diagnosis of blood related diseases through early stage screening. Some of these disorders include leukemia, AIDS, malaria, diabetes and anemia among others. According to UNAIDS, there were about 37.9 million people living with HIV in 2018, out of which, 36.2 million were adults and 1.7 million were children under the age of 15 years. Moreover, the rising new cases of leukemia and growing prevalence of anemia among people is anticipated to further raise the market growth. Increasing expenditure on healthcare on the back of rising awareness among people and growing disposable income in developed and developing countries is estimated to be another growth factor for the market. The growth of medical devices industry on account of technological advancements and increasing number of procedures that require effective utilization of medical devices is predicted to result in a substantial market growth over the forecast period.

Global-Hematology-Diagnostics-Market

Barriers

The low reimbursement rates and large number of patients enrolled for Medicaid have led to a decrease in the number of doctors who accept Medicaid patients over the past few years. This can be attributed to the government reimbursement policies that impact the diagnostic manufacturers’ business. Regulations by the government for monitoring the various characteristics of hematology diagnostic devices such as distribution, production and quality delay the research and development involved in projects which is predicted to restrict the market growth.

Competitive Landscape

Some of the affluent industry leaders in the global hematology diagnostics market are F. Hoffmann-La Roche Ltd, Abbott, Sysmex, Beckman Coulter, Inc., Siemens Healthineers AG, Boule Diagnostics A, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Bio-Rad Laboratories, Inc. and Cellavision. Moreover, other key and niche players are working towards bringing improved and efficient devices for carrying out hematology diagnostics in the market along with investing in the development of high hematology diagnostic devices in order to gain competitive edge in the global hematology diagnostics market.

 

1. INTRODUCTION

1.1. MARKET DEFINITION

1.2. MARKET SEGMENTATION

1.3. PRODUCT OVERVIEW

2. ASSUMPTIONS AND ACRONYMS

3. RESEARCH METHODOLOGY

3.1. VARIABLES (DEPENDENT AND INDEPENDENT)

3.2. MULTI FACTOR BASED SENSITIVITY MODEL

4. EXECUTIVE SUMMARY - GLOBAL HEMATOLOGY DIAGNOSTICS  MARKET

5. KEY MARKET OPPORTUNITIES

6. REGULATORY LANDSCAPE

7. LIST OF DEVICES

7.1. HEMATOLOGY DIAGNOSTICS

7.2. COMPANION DIAGNOSTICS

8. OVERVIEW OF APPLICATIONS OF COMPANION DIAGNOSTICS IN PHARMACODYNAMICS/PHARMACOKINETICS

9. ANALYSIS OF MARKET DYNAMICS

9.1. DRIVERS

9.2. RESTRAINTS

9.3. TRENDS

10. MARKET RISK ANALYSIS

10.1. DEMAND RISK ANALYSIS

10.2. SUPPLY RISK ANALYSIS

11. GLOBAL HEMATOLOGY DIAGNOSTICS  MARKET OUTLOOK

11.1. MARKET SIZE AND FORECAST, 2018-2027

11.1.1. BY VALUE (USD MILLION)

11.2.GLOBAL HEMATOLOGY DIAGNOSTICS  MARKET SEGMENTATION, 2018-2027

11.2.1. BY PRODUCT

o  REAGENTS, INSTRUMENTS & ANALYZERS AND SOFTWARE & SERVICES, 2018-2027F (USD MILLION)

11.2.2. BY PORTABILITY

o  POINT-OF-CARE (POC) DEVICES AND STANDALONE, 2018-2027F (USD MILLION)

11.2.3. BY APPLICATIONS

o  ONCOLOGY, MALARIA, ANEMIA, BOOD COUNT, PLATELET FUNCTION, AND OTHERS (HIV, DIABETES, RARE GENETIC DISORDERS), 2018-2027F (USD MILLION)

·ANEMIA: SICKLE CELL ANEMIA, THALASSEMIA AND OTHERS (VITAMIN DEFICIENCY ANEMIA, IRON DEFICIENCY ANEMIA), 2018-2027F (USD MILLION)

11.2.4. BY END USER

o  HOSPITALS, DIAGNOSTIC LABS, AMBULATORY SURGICAL CENTERS, CLINICS AND OTHERS (RESEARCH & EDUCATIONAL INSTITUTES), 2018-2027F (USD MILLION)

12.  NORTH AMERICA HEMATOLOGY DIAGNOSTICS  MARKET OUTLOOK

12.1.MARKET SIZE AND FORECAST, 2018-2027

12.1.1. BY VALUE (USD MILLION)

12.2. MACROECONOMIC INDICATORS, BY COUNTRY

12.3. NORTH AMERICA HEMATOLOGY DIAGNOSTICS  MARKET SEGMENTATION, 2018-2027

12.3.1. BY PRODUCT

o  REAGENTS, INSTRUMENTS & ANALYZERS AND SOFTWARE & SERVICES, 2018-2027F (USD MILLION)

12.3.2.BY PORTABILITY

o  POINT-OF-CARE (POC) DEVICES AND STANDALONE, 2018-2027F (USD MILLION)

12.3.3.BY APPLICATIONS

o  ONCOLOGY, MALARIA, ANEMIA, BOOD COUNT, PLATELET FUNCTION, AND OTHERS (HIV, DIABETES, RARE GENETIC DISORDERS), 2018-2027F (USD MILLION)

·ANEMIA: SICKLE CELL ANEMIA, THALASSEMIA AND OTHERS (VITAMIN DEFICIENCY ANEMIA, IRON DEFICIENCY ANEMIA), 2018-2027F (USD MILLION)

12.3.4.BY END USER

o  HOSPITALS, DIAGNOSTIC LABS, AMBULATORY SURGICAL CENTERS, CLINICS AND OTHERS (RESEARCH & EDUCATIONAL INSTITUTES), 2018-2027F (USD MILLION)

12.3.5.BY COUNTRY

o  US AND CANADA, 2018-2027F (USD MILLION)

13.  EUROPE HEMATOLOGY DIAGNOSTICS  MARKET OUTLOOK

13.1.MARKET SIZE AND FORECAST, 2018-2027

13.1.1. BY VALUE (USD MILLION)

13.2. MACROECONOMIC INDICATORS, BY COUNTRY

13.3. EUROPE HEMATOLOGY DIAGNOSTICS  MARKET SEGMENTATION, 2018-2027

13.3.1. BY PRODUCT

o  REAGENTS, INSTRUMENTS & ANALYZERS AND SOFTWARE & SERVICES, 2018-2027F (USD MILLION)

13.3.2.BY PORTABILITY

oPOINT-OF-CARE (POC) DEVICES AND STANDALONE, 2018-2027F (USD MILLION)

13.3.3.BY APPLICATIONS

o  ONCOLOGY, MALARIA, ANEMIA, BOOD COUNT, PLATELET FUNCTION, AND OTHERS (HIV, DIABETES, RARE GENETIC DISORDERS), 2018-2027F (USD MILLION)

·ANEMIA: SICKLE CELL ANEMIA, THALASSEMIA AND OTHERS (VITAMIN DEFICIENCY ANEMIA, IRON DEFICIENCY ANEMIA), 2018-2027F (USD MILLION)

13.3.4.BY END USER

o  HOSPITALS, DIAGNOSTIC LABS, AMBULATORY SURGICAL CENTERS, CLINICS AND OTHERS (RESEARCH & EDUCATIONAL INSTITUTES), 2018-2027F (USD MILLION)

13.3.5.BY COUNTRY

o  UK, GERMANY, FRANCE, ITALY, RUSSIA, SPAIN, AND REST OF EUROPE, 2018-2027F (USD MILLION)

14. ASIA PACIFIC HEMATOLOGY DIAGNOSTICS  MARKET OUTLOOK

14.1.MARKET SIZE AND FORECAST, 2018-2027

14.1.1. BY VALUE (USD MILLION)

14.2. MACROECONOMIC INDICATORS, BY COUNTRY

14.3. ASIA PACIFIC HEMATOLOGY DIAGNOSTICS  MARKET SEGMENTATION, 2018-2027

14.3.1. BY PRODUCT

o  REAGENTS, INSTRUMENTS & ANALYZERS AND SOFTWARE & SERVICES, 2018-2027F (USD MILLION)

14.3.2.BY PORTABILITY

o  POINT-OF-CARE (POC) DEVICES AND STANDALONE, 2018-2027F (USD MILLION)

14.3.3.BY APPLICATIONS

o  ONCOLOGY, MALARIA, ANEMIA, BOOD COUNT, PLATELET FUNCTION, AND OTHERS (HIV, DIABETES, RARE GENETIC DISORDERS), 2018-2027F (USD MILLION)

·ANEMIA: SICKLE CELL ANEMIA, THALASSEMIA AND OTHERS (VITAMIN DEFICIENCY ANEMIA, IRON DEFICIENCY ANEMIA), 2018-2027F (USD MILLION)

14.3.4.BY END USER

o  HOSPITALS, DIAGNOSTIC LABS, AMBULATORY SURGICAL CENTERS, CLINICS AND OTHERS (RESEARCH & EDUCATIONAL INSTITUTES), 2018-2027F (USD MILLION)

14.3.5.BY COUNTRY

o  CHINA, INDIA, JAPAN, MALAYSIA, SOUTH KOREA, AUSTRALIA, AND REST OF ASIA PACIFIC, 2018-2027F (USD MILLION)

15.  LATIN AMERICA  HEMATOLOGY DIAGNOSTICS  MARKET OUTLOOK

15.1.MARKET SIZE AND FORECAST, 2018-2027

15.1.1. BY VALUE (USD MILLION)

15.2. MACROECONOMIC INDICATORS, BY COUNTRY

15.3. LATIN AMERICA  HEMATOLOGY DIAGNOSTICS  MARKET SEGMENTATION, 2018-2027

15.3.1. BY PRODUCT

o  REAGENTS, INSTRUMENTS & ANALYZERS AND SOFTWARE & SERVICES, 2018-2027F (USD MILLION)

15.3.2.BY PORTABILITY

o  POINT-OF-CARE (POC) DEVICES AND STANDALONE, 2018-2027F (USD MILLION)

15.3.3.BY APPLICATIONS

o  ONCOLOGY, MALARIA, ANEMIA, BOOD COUNT, PLATELET FUNCTION, AND OTHERS (HIV, DIABETES, RARE GENETIC DISORDERS), 2018-2027F (USD MILLION)

·ANEMIA: SICKLE CELL ANEMIA, THALASSEMIA AND OTHERS (VITAMIN DEFICIENCY ANEMIA, IRON DEFICIENCY ANEMIA), 2018-2027F (USD MILLION)

15.3.4.BY END USER

o  HOSPITALS, DIAGNOSTIC LABS, AMBULATORY SURGICAL CENTERS, CLINICS AND OTHERS (RESEARCH & EDUCATIONAL INSTITUTES), 2018-2027F (USD MILLION)

15.3.5.BY COUNTRY

o  MEXICO, BRAZIL AND REST OF LATIN AMERICA, 2018-2027F (USD MILLION)

16. MIDDLE EAST & AFRICA  HEMATOLOGY DIAGNOSTICS  MARKET OUTLOOK

16.1.MARKET SIZE AND FORECAST, 2018-2027

16.1.1. BY VALUE (USD MILLION)

16.2. MACROECONOMIC INDICATORS, BY COUNTRY

16.3. MIDDLE EAST & AFRICA  HEMATOLOGY DIAGNOSTICS  MARKET SEGMENTATION, 2018-2027

16.3.1. BY PRODUCT

o  REAGENTS, INSTRUMENTS & ANALYZERS AND SOFTWARE & SERVICES, 2018-2027F (USD MILLION)

16.3.2.BY PORTABILITY

o  POINT-OF-CARE (POC) DEVICES AND STANDALONE, 2018-2027F (USD MILLION)

16.3.3.BY APPLICATIONS

o  ONCOLOGY, MALARIA, ANEMIA, BOOD COUNT, PLATELET FUNCTION, AND OTHERS (HIV, DIABETES, RARE GENETIC DISORDERS), 2018-2027F (USD MILLION)

·ANEMIA: SICKLE CELL ANEMIA, THALASSEMIA AND OTHERS (VITAMIN DEFICIENCY ANEMIA, IRON DEFICIENCY ANEMIA), 2018-2027F (USD MILLION)

16.3.4.BY END USER

o  HOSPITALS, DIAGNOSTIC LABS, AMBULATORY SURGICAL CENTERS, CLINICS AND OTHERS (RESEARCH & EDUCATIONAL INSTITUTES), 2018-2027F (USD MILLION)

16.3.5.BY COUNTRY

o  ISRAEL, SOUTH AFRICA, SAUDI ARABIA, UAE, AND REST OF MIDDLE EAST & AFRICA, 2018-2027F (USD MILLION)

17. COMPETITIVE STRUCTURE

17.1. DETAILED OVERVIEW

17.2. ASSESSMENT OF KEY PRODUCT OFFERINGS

17.3. ANALYSIS OF GROWTH STRATEGIES 

17.4. EXHAUSTIVE ANALYSIS ON KEY FINACIAL INDICATORS

17.5. REGIONAL PRESENCE

17.6. KEY PARTNERS AND COLLABORATIONS

17.7. RECENT NEWS AND DEVELOPMENTS

17.8. COMPANY PROFILES

o ABBOTT

o SYSMEX

o BECKMAN COULTER, INC.

o SIEMENS HEALTHCARE GMBH

o BOULE DIAGNOSTICS AB

o F. HOFFMANN-LA ROCHE LTD

o SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.

o BIO-RAD LABORATORIES, INC.

o CELLAVISION

o OTHER PROMINENT PLAYERS

18. STRATEGIC RECOMMENDATIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2020 Research Nester. All Rights Reserved